THU0208 Effectiveness and safety of certolizumab pegol in rheumatoid arthritispatients after failure to antitnf or naÏve patients in real world setting. one year follow-up experience

Abstract

BackgroundBetween 30%–40% of patients with rheumatoid arthritis (RA) discontinue at their first line biological therapy due to inadequate response or adverse events. There is currently a great controversy about using...